SavedAdd your journal

Journals / Current Research in Dental Sciences / 2008 / Cilt: 2008 - Sayı: 3

KEMİK METASTAZI YAPMIŞ PROSTAT KANSERİ TEDAVİSİNDE KULLANILAN BİFOSFONATA BAĞLI OLARAK

Dr. Dt. Zühre Zafersoy AKARSLAN
Dr. Dt. Sevil Altundağ KAHRAMAN
Pages
105–110
Publication Date
2008-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

prostat olan bifosfonatlara bağlı olarak mandibulada osteonekroz gelişen bir vakanın sunulması, osteonekrozun teşhis ve tedavisine yönelik uygulamaların güncel literatür bilgisi ışığında değerlendirilmesidir

🔖

Cite This Article

AKARSLAN, D. D. Z. Z., KAHRAMAN, D. D. S. A. (2008). KEMİK METASTAZI YAPMIŞ PROSTAT KANSERİ TEDAVİSİNDE KULLANILAN BİFOSFONATA BAĞLI OLARAK. Current Research in Dental Sciences, Cilt: 2008 - Sayı: 3, 105–110. https://ajindex.com/articles/736316

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Coleman RE. Metastatic bone disease: clinical features, strategies. Cancer Treat Rev 2001; 27(3): 165-76.
  2. Gracia-Sanez JA, Lopez-Tarruella S, Gracia-Paredes B, Rodriguez-Lajusticia L, Villalobos L, Diaz-Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Pathol Oral Cir Bucal 2007; 12(5): E351-6. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK. A double blind, placebo controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (mrc pr05Trail). J Natl Cancer 2003; 95(17): 1300-11. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4(1):30-4. Fleish H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19(1): 80-100.
  3. Lobato JV, Mauricio AC, Rodgigues JM, Cavaleiro MV, Cortez PP, Xavier L, Botelho C, Hussain NS, Santos JD. Jaw avasculer osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg 2008; 61(1):99-106.
  4. Walter C, Grötz GA, Kunkel M, Al-Nawas B. Prevlance of bifosfonat associated osteoncrosis of the jaw within field of osteonecrosis. Support Care Cancer 2007; 15(2): 197-202. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2): 75- 85. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83(6): 1930-5.
  5. Hughes DE, Wright KR Uy HL. Sasaki A, Yoneda T. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 1995; 10(10): 1478-87.
  6. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17(2): 137-44. Reilly MM. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy. Oncol Nurs Forum 2007; 34(2):301-5.
  7. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34):8580-7.
  8. Woo SK, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Inter Med 2006; 144